{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:57:38Z","timestamp":1789444658142,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.bcp.2008.08.004","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T08:11:48Z","timestamp":1218615108000},"page":"1134-1141","source":"Crossref","is-referenced-by-count":7,"title":["Identification of novel selective V2 receptor non-peptide agonists"],"prefix":"10.1016","volume":"76","author":[{"given":"Andria L.","family":"Del Tredici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sine M.","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman R.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelveh","family":"Lameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika A.","family":"Currier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Brann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mohell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Piu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2008.08.004_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1043-2760(00)00304-0","article-title":"Vasopressin receptors","volume":"11","author":"Birnbaumer","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bcp.2008.08.004_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","article-title":"Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo","volume":"282","author":"Tahara","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.08.004_bib3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/sj.bjp.0702220","article-title":"Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells","volume":"125","author":"Tahara","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0008-6363(01)00337-6","article-title":"The V2 vasopressin receptor mutations and fluid homeostasis","volume":"51","author":"Birnbaumer","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.bcp.2008.08.004_bib5","doi-asserted-by":"crossref","first-page":"F257","DOI":"10.1152\/ajprenal.00491.2005","article-title":"Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus","volume":"291","author":"Robben","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bcp.2008.08.004_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.ackd.2006.01.006","article-title":"Nephrogenic diabetes insipidus","volume":"13","author":"Bichet","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.bcp.2008.08.004_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00558266","article-title":"Pharmacokinetics and haematological effects of desmopressin","volume":"35","author":"Kohler","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0006-2952(97)00070-1","article-title":"1-Desamino-8-d-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor","volume":"53","author":"Saito","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib9","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","article-title":"Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders","volume":"99","author":"Griebel","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2008.08.004_bib10","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1210\/jcem.84.6.5723","article-title":"Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity","volume":"84","author":"Dinan","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2008.08.004_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S0033291703001004","article-title":"Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression","volume":"34","author":"Dinan","year":"2004","journal-title":"Psychol Med"},{"key":"10.1016\/j.bcp.2008.08.004_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2265.1999.00850.x","article-title":"ACTH and cortisol release following intravenous desmopressin: a dose\u2013response study","volume":"51","author":"Scott","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bcp.2008.08.004_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2265.1997.1330954.x","article-title":"Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess","volume":"46","author":"Colombo","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bcp.2008.08.004_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2265.1986.tb03258.x","article-title":"Hormonal and cardiovascular responses to DDAVP in man","volume":"24","author":"Williams","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.bcp.2008.08.004_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1254\/jphs.93.484","article-title":"Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats","volume":"93","author":"Nakamura","year":"2003","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.bcp.2008.08.004_bib16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1254\/jphs.94.426","article-title":"Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs","volume":"94","author":"Nakamura","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.bcp.2008.08.004_bib17","first-page":"1005","article-title":"Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats","volume":"295","author":"Nakamura","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.08.004_bib18","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.bjp.0703221","article-title":"Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes","volume":"129","author":"Nakamura","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1742-7843.2006.pto_299.x","article-title":"The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease","volume":"99","author":"Petersen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2008.08.004_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0014-2999(95)00639-7","article-title":"Pharmacology of muscarinic acetylcholine receptor subtypes (m1\u2013m5): high throughput assays in mammalian cells","volume":"295","author":"Brauner-Osborne","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","article-title":"5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics","volume":"299","author":"Weiner","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2008.08.004_bib22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1124\/mol.61.6.1297","article-title":"Discovery of an ectopic activation site on the M(1) muscarinic receptor","volume":"61","author":"Spalding","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib23","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2174\/138161206776873662","article-title":"Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout","volume":"12","author":"Burstein","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bcp.2008.08.004_bib24","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.onc.1202067","article-title":"The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors","volume":"17","author":"Burstein","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2008.08.004_bib25","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1038\/sj.onc.1205444","article-title":"Dissection of the cytoplasmic domains of cytokine receptors involved in STAT and Ras dependent proliferation","volume":"21","author":"Piu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2008.08.004_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.onc.1209024","article-title":"Beta-arrestin 2 modulates the activity of nuclear receptor RAR beta2 through activation of ERK2 kinase","volume":"25","author":"Piu","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2008.08.004_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bcp.2005.10.025","article-title":"Identification of novel subtype selective RAR agonists","volume":"71","author":"Piu","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.onc.1207014","article-title":"G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway","volume":"23","author":"Weissman","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2008.08.004_bib29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/mol.107.034298","article-title":"Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists","volume":"72","author":"Ma","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2008.08.004_bib30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/329839a0","article-title":"No requirements of cyclic conformation of antagonists in binding to vasopressin receptors","volume":"329","author":"Manning","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2008.08.004_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bcp.2008.08.004_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J Comb Chem"},{"key":"10.1016\/j.bcp.2008.08.004_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1210\/me.2006-0202","article-title":"Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors","volume":"21","author":"Rodrigo","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bcp.2008.08.004_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0014-5793(93)81149-T","article-title":"Oxytocin induced cAMP-dependent protein kinase activation and urokinase-type plasminogen activator production in LLC-PK1 renal epithelial cells is mediated by the vasopressin V2-receptor","volume":"315","author":"Jans","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2008.08.004_bib35","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1172\/JCI119098","article-title":"Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist","volume":"98","author":"Serradeil-Le Gal","year":"1996","journal-title":"J Clin Invest"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295208005339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295208005339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T12:40:58Z","timestamp":1738327258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295208005339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0006295208005339"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2008.08.004","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}